Status:
COMPLETED
A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants
Lead Sponsor:
Celgene
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a Phase 1 study that will be conducted in 2 parts. Participants may participate in 1 part only. * Part 1 will be a randomized, double-blind, placebo-controlled, single ascending dose study to...
Eligibility Criteria
Inclusion
- Participants must satisfy the following criteria to be enrolled in the study:
- Must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments/procedures being conducted.
- Healthy adult female of nonchildbearing potential or male of any race, between 18 to 55 years of age (inclusive) at the time of signing the ICF, and in good health as determined by the screening history and Physical examination (PE).
- Agrees to abide by the requirements and restrictions outlined in the CC-92480 Pregnancy Prevention Plan for Participants in Clinical Trials.
- For males:
- a. Practice true abstinence (which must be reviewed on a monthly basis, as applicable) or agree to use a barrier contraception not made of natural (animal) membrane (eg, latex or polyurethane condoms are acceptable) when engaging in sexual activity with a female of childbearing potential (FCBP) while on study medication, and for at 3 months after the last dose of study medication even if he has undergone a successful vasectomy.
- For females:
- Female participants must have been surgically sterilized (hysterectomy or bilateral oophorectomy; proper documentation required) at least 6 months before screening or be postmenopausal (defined as 24 months without menses before screening, with a serum follicle-stimulation hormone (FSH) level of \> 40 IU/L at screening.
- Must have a body mass index between 18 and 33 kg/m2 (inclusive) at the time of signing the ICF.
- Clinical laboratory test results must be within the respective reference ranges; or if not, the results be clinically insignificant according to the Investigator's medical judgment.
- Participant must agree and be willing to consume a standard high-fat meal (which may contain gluten), for Part 2 participants only.
Exclusion
- The presence of any of the following will exclude a participant from enrollment:
- Female of childbearing potential, pregnant, or breastfeeding.
- History of any clinically significant and relevant neurological, gastrointestinal (GI), renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders as determined by the Investigator.
- History of severe (eg, anaphylactic, anaphylactoid, Stevens-Johnson, angioedematous) reaction to a drug, or adverse reactions to multiple drugs.
- Use of any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 28 days of the first dose administration.
- Use of any nonprescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration.
- Donation of blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.
- History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual \[DSM\]) within 2 years before first dose administration, or positive drug screening test reflecting consumption of illicit drugs.
- History of alcohol abuse (as defined by the current version of the DSM) within 2 years before first dose administration, or positive alcohol screen.
- Known to have serum hepatitis or known to be a carrier of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV Ab), or have a reactive result to the test for human immunodeficiency virus (HIV) antibodies at screening.
- Use of tobacco- or nicotine-containing products within 3 months prior to Day -1, as assessed by medical history and physical examination, or positive urine cotinine test at screening.
- Vaccination within 30 days of first dose administration or plans to receive vaccination (live and attenuated) within 30 days after dosing.
Key Trial Info
Start Date :
January 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 8 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04839809
Start Date
January 19 2021
End Date
October 8 2021
Last Update
December 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PPD Phase 1 Clinic
Austin, Texas, United States, 78744